Comparative Efficacy of Biologic Therapies for Psoriasis: Insights from Head-to-Head Studies
Year: 2026
Type: article
Abstract: Biologic therapies have substantially transformed the management of moderate-to-severe psoriasis, but differences in efficacy, speed of response, durability, and safety reflect the distinct immunological pathways targeted by individual agents. The aim of this review is the analysis and comparison of particular biological agents in terms of efficacy and safety. Head-to-head trials consistently demonstrate that IL-17 and IL-23 inhibitors achieve greater skin clearance than first-generation TNF-α inhibitors. IL-17 blockade, particularly with agents targeting IL-17A, produces rapid clinical improvement by directly suppressing keratinocyte-driven inflammation. Dual IL-17A/IL-17F inhibition with bimekizumab may provide even greater clearance, although broader IL-17 inhibition is associated with a higher frequency of mucosal candidiasis. In contrast, selective IL-23 inhibition acts upstream by suppressing the differentiation and maintenance of pathogenic Th17 cells and appears to provide particularly durable disease control. Selective IL-23 inhibitors may also preserve potentially protective IL-12 signaling, distinguishing them from ustekinumab, which targets the shared p40 subunit. Safety profiles are generally favorable across biologic classes, although mechanism-specific risks include tuberculosis reactivation with TNF-α inhibitors, candidiasis with IL-17 inhibitors, and inflammatory bowel disease concerns with IL-17 blockade. Therefore, biologic selection should be individualized according to disease severity, required speed and durability of response, comorbidities, affected anatomical sites, safety considerations, dosing frequency, patient preferences and adherence goals. Current comparative evidence supports increasingly targeted approaches within the IL-23/IL-17 axis.
Institution: Medical University of Białystok
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,499
OpenAlex ID: W7236238662
